# Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection

> **NCT06406816** · EARLY_PHASE1 · RECRUITING · sponsor: **Yongyi Zeng** · enrollment: 10 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** Neoantigen Vaccine plus Capecitabine

## Key facts

- **NCT ID:** NCT06406816
- **Lead sponsor:** Yongyi Zeng
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-06
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06406816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06406816, "Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06406816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*